Overview Dividends

(ZEPP) Zepp Health - Ratings and Ratios

Exchange: NYSE • Country: Netherlands • Currency: USD • Type: Common Stock • ISIN: US98945L2043

Smartwatches, Fitness Trackers, Smart Rings

ZEPP EPS (Earnings per Share)

EPS Growth (3Y CAGR): -14.50%
EPS Trend (3Y Correlation): 29.8%

ZEPP Revenue

Revenue Growth (3Y CAGR): -66.54%
Revenue Trend (3Y Correlation): -92.9%

Description: ZEPP Zepp Health

Zepp Health Corp, listed on the NYSE under the ticker symbol ZEPP, is a Dutch company operating in the Electronic Equipment & Instruments sub-industry. The companys market capitalization stands at $186.79 million, indicating a relatively small-cap stock with potential for growth or volatility.

The stocks current price is $33.86, having recently reached a 52-week high of $35.11. With a beta of 0.852, ZEPPs stock exhibits slightly lower volatility compared to the overall market. The average trading volume is approximately 415,041 shares, suggesting moderate liquidity.

From a fundamental analysis perspective, ZEPPs forward Price-to-Earnings ratio is 3.12, which may indicate undervaluation or low expectations for future earnings growth. The Return on Equity (RoE) is -28.84%, signifying that the company is currently unprofitable. Key drivers for ZEPPs financial performance may include sales growth, product innovation, and expansion into new markets, particularly in the wearables and health technology sectors.

To assess ZEPPs potential, key performance indicators (KPIs) such as revenue growth rate, gross margin, and operating expense ratio should be closely monitored. Economic drivers influencing the companys success may include trends in global health and fitness, technological advancements in wearables, and competition within the industry. A thorough analysis of these factors is crucial for making informed investment decisions regarding ZEPP.

ZEPP Stock Overview

Market Cap in USD	487m
Sub-Industry	Electronic Equipment & Instruments
IPO / Inception	2018-02-08

ZEPP Stock Ratings

Growth Rating	-13.8%
Fundamental	18.1%
Dividend Rating	1.0%
Return 12m vs S&P 500	1,036%
Analyst Rating	5.0 of 5

ZEPP Dividends

Currently no dividends paid

ZEPP Growth Ratios

Growth Correlation 3m	95.6%
Growth Correlation 12m	-5.6%
Growth Correlation 5y	-87.4%
CAGR 5y	-4.93%
CAGR/Max DD 5y	-0.05
Sharpe Ratio 12m	-0.03
Alpha	987.89
Beta	0.540
Volatility	112.34%
Current Volume	203k
Average Volume 20d	656.8k
Stop Loss	35.3 (-7%)
Signal	-0.35

Piotroski VR‑10 (Strict, 0-10) 2.0

Net Income (-77.6m TTM) > 0 and > 6% of Revenue (6% = 12.0m TTM)

FCFTA -0.05 (>2.0%) and ΔFCFTA -11.80pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 12.07% (prev 5.11%; Δ 6.96pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.04 (>3.0%) and CFO -24.4m > Net Income -77.6m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 1.10 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (3.96m) change vs 12m ago -93.30% (target <= -2.0% for YES)

Gross Margin 37.52% (prev 36.30%; Δ 1.22pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 35.51% (prev 255.0%; Δ -219.5pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -2.35 (EBITDA TTM -11.5m / Interest Expense TTM 5.34m) >= 6 (WARN >= 3)

Altman Z'' 0.02

(A) 0.04 = (Total Current Assets 272.4m - Total Current Liabilities 248.3m) / Total Assets 549.0m

(B) 0.00 = Retained Earnings (Balance) 1.14m / Total Assets 549.0m

(D) -0.12 = Book Value of Equity -37.8m / Total Liabilities 323.6m

Total Rating: 0.02 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 18.12

1. Piotroski 2.0pt = -3.0

2. FCF Yield -4.16% = -2.08

3. FCF Margin -12.94% = -4.85

4. Debt/Equity 0.85 = 2.15

5. Debt/Ebitda -16.69 = -2.50

6. ROIC - WACC -8.71% = -10.88

7. RoE -30.34% = -2.50

8. Rev. Trend -92.93% = -4.65

9. Rev. CAGR -66.54% = -2.50

10. EPS Trend 29.78% = 0.74

11. EPS CAGR -14.50% = -1.81

What is the price of ZEPP shares?

As of August 29, 2025, the stock is trading at USD 37.96 with a total of 202,998 shares traded.
Over the past week, the price has changed by -5.10%, over one month by +176.47%, over three months by +1418.40% and over the past year by +1236.62%.

Is Zepp Health a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Zepp Health (NYSE:ZEPP) is currently (August 2025) a stock to sell. It has a ValueRay Fundamental Rating of 18.12 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ZEPP is around 40.02 USD . This means that ZEPP is currently overvalued and has a potential downside of 5.43%.

Is ZEPP a buy, sell or hold?

Zepp Health has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy ZEPP.

Strong Buy: 1
Buy: 0
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ZEPP price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	12.3	-67.5%
Analysts Target Price	12.3	-67.5%
ValueRay Target Price	43.6	14.8%

Last update: 2025-08-18 02:04

ZEPP Fundamental Data Overview

Market Cap USD = 486.5m (486.5m USD * 1.0 USD.USD)
CCE Cash And Equivalents = 56.5m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 3.124
P/S = 2.4332
P/B = 2.1585
Beta = 1.123
Revenue TTM = 199.9m USD
EBIT TTM = -12.5m USD
EBITDA TTM = -11.5m USD
Long Term Debt = 70.4m USD (from longTermDebt, last quarter)
Short Term Debt = 121.7m USD (from shortTermDebt, last quarter)
Debt = 192.1m USD (Calculated: Short Term 121.7m + Long Term 70.4m)
Net Debt = 138.2m USD (from netDebt column, last quarter)
Enterprise Value = 622.1m USD (486.5m + Debt 192.1m - CCE 56.5m)
Interest Coverage Ratio = -2.35 (Ebit TTM -12.5m / Interest Expense TTM 5.34m)
FCF Yield = -4.16% (FCF TTM -25.9m / Enterprise Value 622.1m)
FCF Margin = -12.94% (FCF TTM -25.9m / Revenue TTM 199.9m)
Net Margin = -38.81% (Net Income TTM -77.6m / Revenue TTM 199.9m)
Gross Margin = 37.52% ((Revenue TTM 199.9m - Cost of Revenue TTM 124.9m) / Revenue TTM)
Tobins Q-Ratio = -16.45 (set to none) (Enterprise Value 622.1m / Book Value Of Equity -37.8m)
Interest Expense / Debt = 0.65% (Interest Expense 1.25m / Debt 192.1m)
Taxrate = 21.0% (US default)
NOPAT = -12.5m (EBIT -12.5m, no tax applied on loss)
Current Ratio = 1.10 (Total Current Assets 272.4m / Total Current Liabilities 248.3m)
Debt / Equity = 0.85 (Debt 192.1m / last Quarter total Stockholder Equity 225.4m)
Debt / EBITDA = -16.69 (Net Debt 138.2m / EBITDA -11.5m)
Debt / FCF = -7.42 (Debt 192.1m / FCF TTM -25.9m)
Total Stockholder Equity = 255.8m (last 4 quarters mean)
RoA = -14.14% (Net Income -77.6m, Total Assets 549.0m )
RoE = -30.34% (Net Income TTM -77.6m / Total Stockholder Equity 255.8m)
RoCE = -3.84% (Ebit -12.5m / (Equity 255.8m + L.T.Debt 70.4m))
RoIC = -2.83% (NOPAT -12.5m / Invested Capital 443.5m)
WACC = 5.88% (E(486.5m)/V(678.6m) * Re(8.0%)) + (D(192.1m)/V(678.6m) * Rd(0.65%) * (1-Tc(0.21)))
Shares Correlation 5-Years: -30.0 | Cagr: -50.52%
Discount Rate = 8.0% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -25.9m)
Revenue Correlation: -92.93 | Revenue CAGR: -66.54%
Rev Growth-of-Growth: -52.65
EPS Correlation: 29.78 | EPS CAGR: -14.50%
EPS Growth-of-Growth: -117.6

Additional Sources for ZEPP Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle